BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TONIX Pharmaceuticals, Inc. Release: Combatting the Enemy Many Veterans Bring Home: Post-Traumatic Stress Disorder


9/26/2013 10:16:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Sept. 26, 2013 /PRNewswire/ -- In Shakespeare's Hamlet, the Prince of Denmark complains about his troubled mind, wishing for a restful sleep with these words: "To be, or not to be, that is the question: Whether 'tis nobler in the mind to suffer the slings and arrows of outrageous Fortune, or to take arms against a sea of troubles, and by opposing end them: to die, to sleep no more; and by a sleep, to say we end the heart-ache and the thousand natural shocks that flesh is heir to?"

Sadly, restful sleep is as elusive to many returning veterans as it was for Hamlet, who kept reliving the horrific vision of his mother murdering the King, his father, in order to marry his uncle. According to the Mayo Clinic, post-traumatic stress disorder (PTSD) is a mental health condition that is triggered by a terrifying event. Symptoms may include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event.

Our returning warriors comprise the largest group of PTSD patients, but they are not alone. Civilian PTSD can be triggered by serious accidents, disasters, terrorist attacks, violent personal assaults, sexual abuse, emotional losses and ICU stays. What more can be done to help "end the heartache and the thousand natural shocks that flesh is heir to" for those suffering, and assure them not just a more restful sleep, but a restorative night's sleep?

There may be a vicious cycle involving poor sleep quality and the severity of daytime symptoms of PTSD. Specifically, it is believed that unrestorative sleep can exacerbate the other symptoms of the disorder, which in turn can make restful sleep even more difficult to achieve.

There are two FDA-approved products for PTSD, but their use can be limited by side effects. Other anti-anxiety and sleep medicines are sometimes helpful, but prescription sleep medicines are not ideal due to their short-term efficacy and safety concerns. There is clearly an unmet need for a non-habit forming, safe, pharmaceutical option.

Seth Lederman, M.D., co-founder, President and CEO of New York City-based Tonix Pharmaceuticals, may have the answer. Dr. Ledermana physician, scientist and experienced inventor and developer of prescription pharmaceuticalsbelieves (and clinical studies continue to bear out) that his company's investigational therapy TNX-102 SL could change PTSD outcomes. This novel treatment is based on cyclobenzaprine (CBP), a compound that has been FDA-approved as a muscle relaxant since 1977 for short-term use over a range of doses. Tonix is determining if TNX-102 SL, administered as a low-dose sublingual tablet at bedtime, can improve the symptoms of PTSDand help restore that elusive good night's sleep. Tonix is currently planning for a clinical study of TNX-102 SL in PTSD.

For more information, visit www.tonixpharma.com.

Contact: Laura Radocaj, Dian Griesel Int'l. 212.825.3210

SOURCE Tonix Pharmaceuticals



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES